The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...
KRN Heat Exchanger IPO: Details & ... Sep 17, 2024 11:29 Gaurs Group Plans IPO in 18 Months Amid Realty Boom Gaurs Group, a leading real estate developer, plans to launch its IPO in the next 18 ...